Reduced incidence of hyperkalemia and azotemia in patients receiving sulindac compared with indomethacin.
The incidence and severity of hyperkalemia and azotemia was investigated in a prospective randomized study involving 74 patients receiving either sulindac 200 mg p.o. b.i.d. or indomethacin 25 mg p.o. t.i.d. and 100 mg p.r. The mean +/- SE posttreatment increment in serum potassium was 0.8 +/- 0.1 mmol/l in patients treated by indomethacin compared to 0.5 +/- 0.1 in those receiving sulindac (p less than 0.025). The mean +/- SE posttreatment increment in blood urea nitrogen (BUN) was 3.1 +/- 0.4 mmol/l in patients on indomethacin compared to only 0.9 +/- 0.3 in patients on sulindac (p less than 0.001). In 5 patients who developed hyperkalemia while on indomethacin, changing to sulindac resulted in a sharp reduction of serum potassium in 3, and normalization of BUN in all patients. These data support the claim of a reduced risk of impaired renal function associated with the use of sulindac.
Nesher
G
G
Department of Medicine, Shaare Zedek Medical Center Jerusalem, Israel.
Zimran
A
A
Hershko
C
C
D000368:Aged; D000369:Aged, 80 and over; D001806:Blood Urea Nitrogen; D005260:Female; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced* / Q000453:epidemiology; D007192:Indenes / Q000009:adverse effects*; D007213:Indomethacin / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011446:Prospective Studies; D011897:Random Allocation; D013467:Sulindac / Q000009:adverse effects*; D014511:Uremia / Q000139:chemically induced* / Q000453:epidemiology
D007192:Indenes; D013467:Sulindac; D011188:Potassium; D007213:Indomethacin